恩替卡韦对慢性乙型肝炎患者抗病毒的临床疗效及其对肝功能指标的影响被引量：8

下载PDF

导出

摘要目的:评价恩替卡韦对慢性乙型肝炎(CHB)患者抗病毒感染的临床疗效及其对肝功能指标的影响。方法:选取2014年7月—2016年1 2月间收治的CHB患者50例资料,按数字表法将其分为对照组和观察组,每组25例;对照组患者给予阿德福韦酯治疗;观察组患者给予恩替卡韦治疗,比较两组患者治疗后总有效率的差异,以及治疗前后肝功能各指标(ALT、HBV-DNA)的改善情况。结果:观察组患者治疗后的有效率为92.00%高于对照组为68.00%(P<0.05),ALT、HBV-DNA测得值分别为(41.10±6.54)U/L和(277.67±0.28)U/L低于对照组分别为(49.98±6.59)U/L和(1 640.88±0.09)U/L(P<0.05),HBe Ag转阴率为40.00%略高于对照组为36.0%但经比较其差异无统计学意义(P>0.05),用药期间不良反应的发生率为8.00%低于对照组为36.00%(P<0.05)。结论:采用恩替卡韦治疗CHB患者抗病毒感染的疗效优于阿德福韦酯,并能有效改善其肝功能各指标,且安全性较高。

作者李慧霞

机构地区中国人民解放军第九十一中心医院

出处《抗感染药学》 2017年第8期1495-1496,1534,共3页 Anti-infection Pharmacy

关键词恩替卡韦慢性乙型肝炎病毒感染晦床效果

分类号 R969.3 [医药卫生—药理学]

引文网络
相关文献

参考文献5

1姜波,李忠,张宇.恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析[J].中华医院感染学杂志,2014,24(16):3972-3974. 被引量：12
2吴取梅,赵久法.恩替卡韦治疗慢性乙型肝炎病毒感染的研究进展[J].中华全科医学,2016,14(10):1742-1744. 被引量：17
3许正锯,潘兴南,魏梅娟,刘立飞,刘理冠,杨环文,刘钎,黄志杰.慢性乙型肝炎病毒感染者恩替卡韦抗病毒治疗前后血清高尔基体蛋白GP73的变化[J].中华实验和临床感染病杂志（电子版）,2016,10(3):298-303. 被引量：5
4肖兰春,陈利.恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析[J].中外医疗,2017,36(13):137-139. 被引量：5
5梁世寅.恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效观察[J].现代诊断与治疗,2015,26(15):3432-3433. 被引量：5

二级参考文献45

1Mustafa Kemal C,Tuba D, Celal A, et al. Four-year study of entecavir efficacy and safety in nucleos (t)ide-naive HBeAg positive chronic hepatitis B patients[J]. Acta Clinica Croatica,2014,53(1) :31-36.
2Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir re- duces the risk of liver disease progression in nucleos (t) ide analogue- experienced HBV-infected patients with prior resistant mutants [ J ]. Journal of Antimicrobial Chemotherapy ,2013,68 ( 9 ) :2154-2163.
3Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naYve chronic hepatitis B patients in the US-the ENUMERATE study [ J 1. Alimentary Pharmacology & Thera- peutics,2015,43 ( 1 ) : 134-144.
4Tsai MC, Chen CH, Hung CH, et al. A comparison of efficacy and safe- ty of 2-year telbivudine and entecavir treatment in patients with chron- ic hepatitis B:a match-control study [ J ]. Clinical Microbiology and In- fection ,2014,20 ( 2 ) :90-100.
5Wiens A, Lenzi L, Venson R, et al. Comparative Efficacy of Oral Nu- cleoside or Nucleotide Analog Monotherapy Used in Chronic HepatitisB : A Mixed-Treatment Comparison Meta-analysis [ J ]. Phannacothera- py : The Journal of Human Pharmacology and Drug Therapy, 2013,33 (2) :144-151.
6Toy M, Hutton DW, So SK, et al. Cost-Effectiveness and Cost Thresh- olds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China[ J]. Plos One,2015,10( 11 ) :526-535.
7Wiens A, Lenzi L, Venson R, et al. Economic evaluation of treatments for chronic hepatitis B [ J]. The Brazilian Journal of Infectious Disea- ses,2013,17(4) :418-426.
8Wang G, Liu Y, Qiu P, et al. Cost-effectiveness analysis of lamivudi- ne, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance [ J ]. Drug design, development and thera- py,2015,12(9) :2839-2846.
9Preda CM, Baicus C, Negreanu L, et al. Effectiveness of entecavir treatment and predictive factors for virologic response [ J ]. Revista Espanola De Enfermedades Digestivas Organo Oficial De La Sociedad Espanola De Patologia Digestiva, 2014,106 ( 5 ) :305-311.
10Gines PP, Lenz K, Moiler S, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis [ J]. Journal of Hepatology,2010, 53(3) :397-417.